Core Insights - IMPACT Silver Corp. announced high-grade drill results from the Juarez Zone at its Plomosas Mine, with significant intersections including 15.14% ZnEq over 3.07 meters and 24.69% ZnEq over 1.47 meters [1][2][5] Drilling Results - New drill intersections in the Juarez Zone include: - Hole UGMJ-2547: 4.49 meters at 15.14% ZnEq, with a notable interval of 2.15 meters at 24.69% ZnEq [2] - Other holes reported varying grades, with some intervals showing high concentrations of zinc, lead, and silver [2][3] Geological Context - The Juarez Zone is located stratigraphically below the Mina Vieja horizon and has separate access, indicating potential for further exploration [3][4] - Mineralization occurs in carbonate replacement zones across three bedrock units, suggesting a complex geological environment conducive to high-grade deposits [6] Company Strategy and Operations - The CEO expressed satisfaction with the new drill results, highlighting the potential for expanding mining operations into these newly identified areas [5] - The company is actively exploring other targets along a six-kilometer CRD trend, indicating a strategic focus on expanding its resource base [5] Company Overview - IMPACT Silver Corp. operates two mining projects in Mexico, with a focus on high-grade zinc production and exploration potential [7][10] - The Plomosas Mine has been identified as a historic high-grade zinc producer with significant exploration upside, having restarted operations in late 2023 [10]

San Francisco, California--(Newsfile Corp. - November 20, 2025) - A new securities class action lawsuit against CarMax, Inc. (NYSE: KMX) has expanded the alleged class period to now include investors who purchased or otherwise acquired CarMax securities between June 20, 2025 and November 5, 2025.The period has been lengthened to include the severe market reaction to CarMax's announcement that it fired CEO Bill Nash, news which drove the price of CarMax shares down as much as $9.48 (-23%) on November 6, 202 ...

Core Insights - Giga Metals Corp. will host a live virtual corporate update on December 3, 2025, at 2:00 PM ET, inviting current shareholders and interested parties to participate [1] - The webinar will cover commodities including Nickel, Cobalt, Copper, and PGEs, with a live Q&A session to follow [2][4] Company Overview - Giga Metals Corporation's primary asset is the Turnagain Project located in northern British Columbia, which is recognized for its significant undeveloped sulphide nickel and cobalt resources [4] - The Turnagain Project is jointly owned by Giga Metals Corporation and Mitsubishi Corporation through its subsidiary Hard Creek Nickel [4] - A Pre-Feasibility Study for the Turnagain Project was released in October 2023 [4] Project Details - The Turnagain ultramafic complex is also noted for its potential copper, platinum, and palladium mineralization, particularly in the Attic Zone adjacent to the known nickel resource [5]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Nidec Corporation due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Allegations - Nidec Corporation is facing scrutiny following a report of improper accounting practices linked to its management, which led to a significant drop in its stock price [3]. - On September 4, 2025, Nidec's American Depositary Receipts (ADRs) fell by 22.7% after the announcement of the probe into accounting issues [3]. Group 2: Class Action Information - Shareholders who purchased Nidec Corporation securities may be eligible for compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2]. - Interested investors can join the class action by submitting a form or contacting the Rosen Law Firm directly for more information [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Skye Bioscience, Inc. securities between November 4, 2024, and October 3, 2025, due to alleged misleading statements regarding the company's business and product effectiveness [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Skye Bioscience made materially false and misleading statements about its product nimacimab, asserting that it was less effective than represented, which overstated its clinical and commercial prospects [5]. - Investors who purchased Skye securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by January 16, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased securities of Perrigo Company plc during the specified Class Period, highlighting the importance of securing legal counsel before the upcoming deadline for lead plaintiff applications [1][2]. Group 1: Class Action Details - The class action lawsuit pertains to securities purchased between February 27, 2023, and November 4, 2025, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][5]. - Investors wishing to serve as lead plaintiff must file their motion by January 16, 2026, and a lead plaintiff acts on behalf of other class members in directing the litigation [1][3]. Group 2: Allegations Against Perrigo - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business acquired from Nestlé, which suffered from significant underinvestment and required substantial capital expenditures beyond stated estimates [5]. - It is claimed that there were significant manufacturing deficiencies in Perrigo's infant formula facility, leading to overstated financial results, including earnings and cash flow, and that positive statements about the company's business were materially misleading [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, noting its history of achieving significant settlements for investors, including over $438 million in 2019 alone [4]. - The firm has been recognized for its leadership in securities class action settlements, being ranked No. 1 by ISS Securities Class Action Services in 2017 and consistently in the top 4 since 2013 [4].

PreveCeutical Provides Clarification of News Release Announcing Update on Plan of Arrangement with BioGene Therapeutics Inc.November 20, 2025 12:26 PM EST | Source: PreveCeutical Medical Inc.Vancouver, British Columbia--(Newsfile Corp. - November 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, further to its news release of earlier today, the Company wishes to clarify that shareholders of record of November 24, 20 ...

Core Insights - Stonegate Capital Partners has updated its coverage on Incannex Healthcare Inc. (NASDAQ: IXHL), highlighting significant clinical progress in the development of IHL-42X for obstructive sleep apnoea (OSA) [1][7] Clinical Development - In Q4 2025, Incannex reported that IHL-42X achieved statistically significant reductions in the Apnoea-Hypopnoea Index (AHI), with maximum reductions of up to 83% in the high-dose group and 79% in the low-dose group [1][7] - Exit interviews indicated that 57.6% of participants perceived an improvement in their OSA, with many describing the changes as meaningful to their daily lives, including better sleep quality and reduced fatigue [1][7] - IHL-42X was well tolerated, with no serious adverse events reported, suggesting its potential for broad use upon approval [1][7] Financial Overview - As of the quarter-end, Incannex reported cash reserves of $73.3 million, a net loss of $6.4 million, and operating expenses of $6.8 million, providing at least twelve months of financial runway [7]

Core Insights - Metaguest.AI reported a strong revenue growth of 91% year-over-year for the nine-month period ending September 30, 2025, reaching $1,930,477 compared to $1,008,901 in the previous year [2] - The company achieved a three-month revenue increase of 38%, totaling $625,623, driven by broader customer adoption and higher platform engagement [2] - Gross profit for the nine-month period rose by 90% to $1,643,038, up from $864,568 in the prior period [2] - The net loss improved by 30% period-over-period, decreasing to $1,305,425 from $1,873,762, attributed to revenue growth and disciplined cost management [3] - The CEO emphasized the focus on accelerating deployment with hotel partners and expanding the AI-driven guest engagement ecosystem as the company enters 2026 [3] Company Overview - Metaguest.AI is a technology company enhancing guest experiences through advanced AI solutions, providing an end-to-end guest engagement ecosystem [4] - The platform includes features such as on-property e-commerce, real-time service requests, mobile check-out, personalized in-room controls, local experience bookings, and a multilingual virtual concierge [4] - The company's solutions are utilized by hotels, resorts, and short-term rental operators to boost efficiency, drive incremental revenue, and elevate customer satisfaction [4]

Core Insights - Pineapple Financial Inc. has established a Digital Asset Treasury Advisory Board to enhance its strategy of becoming the largest holder and staker of Injective ($INJ) and a leading on-chain mortgage finance platform [1][3] - The Advisory Board includes three members from the Injective Foundation, bringing significant expertise in blockchain technology and decentralized finance [2][3] Group 1: Advisory Board Formation - The newly formed Advisory Board consists of Eric Chen, Mirza Uddin, and Cooper Emmons, who have extensive backgrounds in blockchain and decentralized finance [2][3] - The formation of the Advisory Board is a strategic move following Pineapple's $100 million Injective DAT strategy launched in September 2025 [3] Group 2: Company Strategy and Goals - Pineapple aims to integrate Injective's decentralized financial infrastructure into its mortgage and financial technology operations [3] - The company is focused on bridging fintech and decentralized finance, positioning itself as a first-mover in the Injective ecosystem [3] Group 3: Company Background - Pineapple Financial Inc. is a prominent fintech platform and Canadian mortgage brokerage network, dedicated to enhancing the success of agents and brokers while improving homeowner experiences [4] - The company utilizes advanced cloud-based tools and AI-driven systems to support brokers in helping Canadians achieve homeownership [4]